Immune activation17 Apr 2020 21:58
Clevegen also has promise outside immuno-oncology, as it can switch immune suppression to immune activation in various conditions, such as infectious diseases and vaccine development.
Data from Faron's ongoing MATINS trial has shown, that I) in Clevegen, we potentially have the first macrophage immune checkpoint drug which has promoted immune activation of all dosed patients to date;
Needs to read up about immune activation but not today